שווי כולל של החברה: apollomicsinc.com (APLM)
Apollomics, Inc. (APLM) develops unique drugs to combat tumor resistance, leveraging patent protection to treat rare types of lung cancer. The risks associated with focusing on the US and Chinese markets are mitigated by the presence of drugs in the final stages of testing. The price history on GURU.Markets shows that the business valuation is 17.08, while the company generates revenue through partnerships as it awaits the commercial market launch of its innovations.
APLM (Apollomics): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Apollomics, Inc. (APLM) is developing within an isolated oncotherapy cycle where valuation depends on clinical trial results. These events directly impact market capitalization, adjusting the final sum in the formula. The indicator aggregates equity value and debt, subtracting liquid assets to determine the actual business buyout price. This metric reflects the enterprise's maturity and financial stability. By analyzing the core business value, an investor can assess the company's growth potential or stagnation.